NCT04198727View on ClinicalTrials.gov

Study of the Impact of DPD Activity on the Efficacy of Capecitabine

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

155

Participants

Timeline

Start Date

July 20, 2020

Primary Completion Date

January 31, 2026

Study Completion Date

July 31, 2030

Conditions
Breast Neoplasm Malignant Female
Interventions
OTHER

DPD activity assessment

Phenotyping DPD with enzyme activity measure and uracil dosage

DRUG

Capecitabine

Capecitabine assignement at 1000mg per square meter twice daily, cycle of 21 days, 14 days of intake, 7 days of

Trial Locations (5)

98000

Hôpital Princesse Grâce, Monaco

06800

Clinique Saint Jean, Cagnes-sur-Mer

06250

Centre Azuréen de Cancérologie, Mougins

06105

Clinique St Georges, Nice

06189

Centre Antoine Lacassagne, Nice

Sponsors

Collaborators (1)

Cerbaliance
All Listed Sponsors
collaborator

Cerbaliance

UNKNOWN

lead

Centre Antoine Lacassagne

OTHER